483 related articles for article (PubMed ID: 30962630)
1. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.
Takenaka MC; Gabriely G; Rothhammer V; Mascanfroni ID; Wheeler MA; Chao CC; Gutiérrez-Vázquez C; Kenison J; Tjon EC; Barroso A; Vandeventer T; de Lima KA; Rothweiler S; Mayo L; Ghannam S; Zandee S; Healy L; Sherr D; Farez MF; Prat A; Antel J; Reardon DA; Zhang H; Robson SC; Getz G; Weiner HL; Quintana FJ
Nat Neurosci; 2019 May; 22(5):729-740. PubMed ID: 30962630
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
[TBL] [Abstract][Full Text] [Related]
3. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma.
Hara T; Chanoch-Myers R; Mathewson ND; Myskiw C; Atta L; Bussema L; Eichhorn SW; Greenwald AC; Kinker GS; Rodman C; Gonzalez Castro LN; Wakimoto H; Rozenblatt-Rosen O; Zhuang X; Fan J; Hunter T; Verma IM; Wucherpfennig KW; Regev A; Suvà ML; Tirosh I
Cancer Cell; 2021 Jun; 39(6):779-792.e11. PubMed ID: 34087162
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
[TBL] [Abstract][Full Text] [Related]
5. Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.
Zhang H; Feng L; de Andrade Mello P; Mao C; Near R; Csizmadia E; Chan LL; Enjyoji K; Gao W; Zhao H; Robson SC
J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35775486
[TBL] [Abstract][Full Text] [Related]
6. ID1 expressing macrophages support cancer cell stemness and limit CD8
Shang S; Yang C; Chen F; Xiang RS; Zhang H; Dai SY; Liu J; Lv XX; Zhang C; Liu XT; Zhang Q; Lu SB; Song JW; Yu JJ; Zhou JC; Zhang XW; Cui B; Li PP; Zhu ST; Zhang HZ; Hua F
Nat Commun; 2023 Nov; 14(1):7661. PubMed ID: 37996458
[TBL] [Abstract][Full Text] [Related]
7. L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes.
Schlichtner S; Yasinska IM; Klenova E; Abooali M; Lall GS; Berger SM; Ruggiero S; Cholewa D; Milošević M; Gibbs BF; Fasler-Kan E; Sumbayev VV
Oncoimmunology; 2023; 12(1):2244330. PubMed ID: 37577144
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of tumor-associated macrophages in glioma patients.
Shen Y; Zheng D; Hu D; Ma B; Cai C; Chen W; Zeng J; Luo J; Xiao D; Zhao Y; Wu Z; Jing G; Xie Y
Medicine (Baltimore); 2023 Sep; 102(38):e35298. PubMed ID: 37747032
[TBL] [Abstract][Full Text] [Related]
9. CD39 deletion in TCR-engineered T cells enhances antitumour immunity.
Tsai AK; Stromnes IM
Gut; 2024 Apr; 73(5):716-717. PubMed ID: 37898545
[No Abstract] [Full Text] [Related]
10. Astrocyte immunometabolic regulation of the tumour microenvironment drives glioblastoma pathogenicity.
Perelroizen R; Philosof B; Budick-Harmelin N; Chernobylsky T; Ron A; Katzir R; Shimon D; Tessler A; Adir O; Gaoni-Yogev A; Meyer T; Krivitsky A; Shidlovsky N; Madi A; Ruppin E; Mayo L
Brain; 2022 Sep; 145(9):3288-3307. PubMed ID: 35899587
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition.
Kay KE; Lee J; Hong ES; Beilis J; Dayal S; Wesley E; Mitchell S; Wang SZ; Silver DJ; Volovetz J; Johnson S; McGraw M; Grabowski MM; Lu T; Freytag L; Narayana V; Freytag S; Best SA; Whittle JR; Wang Z; Reizes O; Yu JS; Hazen SL; Brown JM; Bayik D; Lathia JD
bioRxiv; 2023 Nov; ():. PubMed ID: 38014234
[TBL] [Abstract][Full Text] [Related]
12. Publisher Correction: Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1.
Zhou L; Wu D; Zhou Y; Wang D; Fu H; Huang Q; Qin G; Chen J; Lv J; Lai S; Zhang H; Tang K; Ma J; Fiskesund R; Zhang Y; Zhang X; Huang B
Nat Immunol; 2023 Dec; 24(12):2165. PubMed ID: 37935894
[No Abstract] [Full Text] [Related]
13. Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.
Li XY; Moesta AK; Xiao C; Nakamura K; Casey M; Zhang H; Madore J; Lepletier A; Aguilera AR; Sundarrajan A; Jacoberger-Foissac C; Wong C; Dela Cruz T; Welch M; Lerner AG; Spatola BN; Soros VB; Corbin J; Anderson AC; Effern M; Hölzel M; Robson SC; Johnston RL; Waddell N; Smith C; Bald T; Geetha N; Beers C; Teng MWL; Smyth MJ
Cancer Discov; 2019 Dec; 9(12):1754-1773. PubMed ID: 31699796
[TBL] [Abstract][Full Text] [Related]
14. Author Correction: Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.
Takenaka MC; Gabriely G; Rothhammer V; Mascanfroni ID; Wheeler MA; Chao CC; Gutiérrez-Vázquez C; Kenison J; Tjon EC; Barroso A; Vandeventer T; de Lima KA; Rothweiler S; Mayo L; Ghannam S; Zandee S; Healy L; Sherr D; Farez MF; Prat A; Antel J; Reardon DA; Zhang H; Robson SC; Getz G; Weiner HL; Quintana FJ
Nat Neurosci; 2019 Sep; 22(9):1533. PubMed ID: 31197266
[TBL] [Abstract][Full Text] [Related]
15. Negative feedback control of neuronal activity by microglia.
Badimon A; Strasburger HJ; Ayata P; Chen X; Nair A; Ikegami A; Hwang P; Chan AT; Graves SM; Uweru JO; Ledderose C; Kutlu MG; Wheeler MA; Kahan A; Ishikawa M; Wang YC; Loh YE; Jiang JX; Surmeier DJ; Robson SC; Junger WG; Sebra R; Calipari ES; Kenny PJ; Eyo UB; Colonna M; Quintana FJ; Wake H; Gradinaru V; Schaefer A
Nature; 2020 Oct; 586(7829):417-423. PubMed ID: 32999463
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
17. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.
Sadik A; Somarribas Patterson LF; Öztürk S; Mohapatra SR; Panitz V; Secker PF; Pfänder P; Loth S; Salem H; Prentzell MT; Berdel B; Iskar M; Faessler E; Reuter F; Kirst I; Kalter V; Foerster KI; Jäger E; Guevara CR; Sobeh M; Hielscher T; Poschet G; Reinhardt A; Hassel JC; Zapatka M; Hahn U; von Deimling A; Hopf C; Schlichting R; Escher BI; Burhenne J; Haefeli WE; Ishaque N; Böhme A; Schäuble S; Thedieck K; Trump S; Seiffert M; Opitz CA
Cell; 2020 Sep; 182(5):1252-1270.e34. PubMed ID: 32818467
[TBL] [Abstract][Full Text] [Related]
18. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways.
Qian M; Wang S; Guo X; Wang J; Zhang Z; Qiu W; Gao X; Chen Z; Xu J; Zhao R; Xue H; Li G
Oncogene; 2020 Jan; 39(2):428-442. PubMed ID: 31485019
[TBL] [Abstract][Full Text] [Related]
20. Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells.
Klemm F; Maas RR; Bowman RL; Kornete M; Soukup K; Nassiri S; Brouland JP; Iacobuzio-Donahue CA; Brennan C; Tabar V; Gutin PH; Daniel RT; Hegi ME; Joyce JA
Cell; 2020 Jun; 181(7):1643-1660.e17. PubMed ID: 32470396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
